Compare Intikeramik Alamasri Industri Tbk. (IKAI) vs UBC Medical Indonesia Tbk. (LABS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intikeramik Alamasri Industri Tbk. vs UBC Medical Indonesia Tbk. — how do they compare? Intikeramik Alamasri Industri Tbk. trades at Rp21 (market cap 279.42B, 5.2M 24h volume), while UBC Medical Indonesia Tbk. trades at Rp168 (market cap 651.75B, 848.2K 24h volume). The key difference: UBC Medical Indonesia Tbk. is far larger — about 2.3× Intikeramik Alamasri Industri Tbk.'s market cap, and Intikeramik Alamasri Industri Tbk. is more actively traded (5.2M versus 848.2K). Which is the better fit depends on your goals.
| IKAI | LABS | |
|---|---|---|
Market Cap | 279.42B | 651.75B |
Volume | 5.2M | 848.2K |
Lot | 52.01K | 8.48K |
Turnover | 108.1M | 140.51M |
Average Price | 20.79 | 165.66 |
Value | 108.1M | 140.51M |
Indicative Equilibrium Price | 21 | 168 |
Indicative Equilibrium Volume | 8.02K | 50 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intikeramik Alamasri Industri Tbk.
PT Intikeramik Alamasri Industri Tbk (the Company) was established under the name PT Intikeramik Alamasri Indah based on notarial deed No. 38 dated June 26, 1991 and was amended with notarial deed No. 16 dated December 14, 1991, both made by Raden Muhammad Hendarmawan, S.H., Notary in Jakarta. PT Intikeramik Alamasri Industri Tbk is the pioneer of large-scale porcelain tile manufacture in Indonesia and one of the largest producers in the Asia Pacific region. Porcelain tiles are superior in term of strength, durability and design versatility to natural stone as well as other synthetics such as glazed tiles. Porcelain is attractive and affordable for use in both commercial and residential developments and has strong following among international architects and interior designers. Intikeramik is seeking to build a leading profile in markets across Europe, America and Asia drawing upon its reputation for consistency, advanced manufacturing technology, a low cost base and substantial available capacity. The company has consolidation production capacity 6,600,000 m2 /year.
Read more on IKAI →About UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →
